The findings suggest a beneficial effect of switching from ranibizumab to aflibercept in eyes with ongoing chronic anti-VEGF treatment for wet AMD irrespective of previous response to ranibizumab. The gene discussed is VEGFA; the disease is wet macular degeneration.